CoheaHr is an European research consortium funded by the 7th framework program of the European Union (Health-F3-2013-603019). Europe’s leading research institutes on HPV-related diseases are part of the consortium, including in total 12 partners from 11 different European countries. The consortium represents specialists from a wide array of disciplines including epidemiologists, virologists, gynaecologists, pathologists, health economists, molecular biologists, viral transmission modellers and statisticians.
CoheaHr stands for “Comparing health services interventions for the prevention of HPV-related cancer”. The main objective of the consortium was to build a reliable resource on the effectiveness and cost-effectiveness of the different preventive strategies against HPV-related disease. This resource contains:
CoheaHr was divided into five research topics, which included four new implementation studies in the first three research topics. The fourth research topic involved mathematically modelling of both existing data as well as the newly collected data in the CoheaHr studies. The fifth research topic involved building a data-ware house and conducting pooled analyses.
Offering self-sampling for hrHPV testing is a feasible and effective mean for detecting CIN2+ in screening non-attendees but the clinical accuracy of hrHPV self-sampling versus clinician sampling had never been studied in a proper randomized manner.
Screening HPV self-sampling with HPV screening on clinician-collected samples were compared in:
Cancer risk will be significantly reduced in vaccinated women. If screening programmes are not changed for vaccinated women - the number of unnecessary referrals will likely increase, leading to unnecessary costs.
To evaluate the impact of vaccination in screening, two studies were conducted:
Vaccination trials have documented that vaccine efficacy among adult women up to age 45/55 is excellent provided they are HPV negative at the time of vaccination. However, HPV vaccination coverage of adult women in Europe is low to very low.
A multinational study in 9 European countries was conducted to identify global and local determinants of acceptability, HPV vaccine compliance, logistics and programmatic issues of vaccinating women 25-45 years attending routine cervical cancer screening
In order to provide direct estimates of positive and undesired effects of different preventive policies for cervical cancer as well as to estimate parameters of the natural history of HPV infection and pre-cancer/cancer, the following activities were performed:
Mathematical models can be used to describe the natural history of HPV infection and therefore predict the impact of different screening and vaccination strategies at a population level.
As part of the activities conducted within this project, two dynamic transmission models were optimised and extended with the aim to assess different cervical cancer prevention strategies and their cost-effectiveness.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no FP7-F3-2013-603019.